Subject(s)
Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 22/genetics , Lymphoma, Mantle-Cell/genetics , Translocation, Genetic , Asymptomatic Diseases , Blood Cell Count , Bone Marrow/pathology , Female , Humans , Lymphoma, Mantle-Cell/blood , Lymphoma, Mantle-Cell/diagnostic imaging , Lymphoma, Mantle-Cell/pathology , Middle Aged , Positron Emission Tomography Computed TomographyABSTRACT
PURPOSE: CD5 is a T cell marker, aberrantly express in B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL). Other chronic B cell malignancies including hairy cell leukemia (HCL) and B cell prolymphocytic leukemia (B-PLL) are CD5 negative or express this antigen in a weak way. In this study, CD5 expression was investigated in leukemic cells from 42 patients with chronic B cell lymphoproliferative disease. METHODS: We studied the CD5 expression in leukemic cells from 42 patients with chronic B-cell malignancies by flow cytometry. Demographic features such as age, sex and clinical date were also analyzed. RESULTS: There were 22 males and 20 females. The immunophenotyping showed that 35 cases were B-CLL, 3 B-PLL and HCL and one patient was MCL. CD5 expression was present in all B-CLL and MCL. Low expression of CD5 was observed in one patient with B-PLL and negative in all cases of HCL. CONCLUSION: Our date demonstrated that CD5 expression can help distinguish among B-CLL from HCL and B-PLL, but is similar expressed in MCL.
Subject(s)
CD5 Antigens/blood , Flow Cytometry/methods , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis , Lymphoma, B-Cell/diagnosis , Lymphoproliferative Disorders/diagnosis , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Diagnosis, Differential , Female , Humans , Leukemia, Hairy Cell/blood , Leukemia, Hairy Cell/diagnosis , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Lymphocyte Count , Lymphoma, B-Cell/blood , Lymphoma, Mantle-Cell/blood , Lymphoma, Mantle-Cell/diagnosis , Lymphoproliferative Disorders/blood , Male , Middle AgedABSTRACT
OBJETIVOS: CD5 é um marcador normalmente expresso nas células T e de forma aberrante nas células B da leucemia linfocítica crônica (LLC) e no linfoma de células do manto (LCM). Outras doenças linfoproliferativas crônicas como a hairy cell leukemia (HCL) e leukemia prolinfocítica de células B (LPL-B), são geralmente CD5 negativas ou expressam fracamente este antígeno. Neste trabalho investigou-se o padrão de expressão do CD5 em 42 pacientes com doenças linfoproliferativas crônicas de células B (DLC-B). METODOS: Investigamos a expressão de CD5 em células leucêmicas de 42 pacientes com DLC-B através da citometria de fluxo. Dados demográficos, tais como idade e sexo, bem como dados clínicos e laboratoriais também foram analisados. RESULTADOS: A imunofenotipagem mostrou que 35 casos foram LLC, 3 LPL-B, 3 HCL e um caso de LMC. O CD5 mostrou-se fortemente expresso em todos os casos de LLC e LMC. Baixa expressão desse antígeno foi observada em um caso de LPL-B, mostrando-se negativamente expresso em todos os casos de HCL. CONCLUSÃO: Nossos resultados demonstram que o padrão de expressão do CD5 pode auxiliar na distinção entre LLC da HCL e LPL-B, sendo no entanto similares na HCL e LCM.